Equities analysts predict that Crispr Therapeutics AG (NASDAQ:CRSP) will announce $4.45 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Crispr Therapeutics’ earnings. The lowest sales estimate is $500,000.00 and the highest is $11.30 million. Crispr Therapeutics posted sales of $32.33 million during the same quarter last year, which would indicate a negative year over year growth rate of 86.2%. The firm is scheduled to report its next quarterly earnings report on Thursday, March 14th.
According to Zacks, analysts expect that Crispr Therapeutics will report full year sales of $9.10 million for the current year, with estimates ranging from $3.40 million to $23.20 million. For the next financial year, analysts anticipate that the company will post sales of $34.78 million, with estimates ranging from $8.00 million to $91.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that follow Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Thursday, November 8th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.33). Crispr Therapeutics had a negative return on equity of 47.32% and a negative net margin of 331.84%. The company had revenue of $0.56 million for the quarter, compared to analyst estimates of $2.64 million. During the same quarter in the prior year, the firm earned ($0.62) earnings per share. The company’s revenue for the quarter was down 76.6% on a year-over-year basis.
Several brokerages have weighed in on CRSP. Zacks Investment Research upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, September 12th. Cann reiterated a “hold” rating on shares of Crispr Therapeutics in a report on Monday, September 17th. BidaskClub downgraded Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 26th. Raymond James began coverage on Crispr Therapeutics in a report on Thursday, September 20th. They issued an “underperform” rating for the company. Finally, Chardan Capital reiterated a “buy” rating and issued a $72.50 price target on shares of Crispr Therapeutics in a report on Wednesday, August 8th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $62.47.
A number of institutional investors and hedge funds have recently modified their holdings of the business. ARK Investment Management LLC grew its stake in shares of Crispr Therapeutics by 211.2% during the 3rd quarter. ARK Investment Management LLC now owns 1,453,590 shares of the company’s stock valued at $64,467,000 after buying an additional 986,450 shares during the period. BlackRock Inc. grew its stake in shares of Crispr Therapeutics by 19.6% during the 3rd quarter. BlackRock Inc. now owns 709,643 shares of the company’s stock valued at $31,471,000 after buying an additional 116,116 shares during the period. Federated Investors Inc. PA purchased a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at $37,101,000. Jennison Associates LLC purchased a new stake in shares of Crispr Therapeutics during the 3rd quarter valued at $23,988,000. Finally, Global Thematic Partners LLC grew its stake in shares of Crispr Therapeutics by 87.7% during the 3rd quarter. Global Thematic Partners LLC now owns 497,276 shares of the company’s stock valued at $22,054,000 after buying an additional 232,362 shares during the period. Institutional investors own 39.49% of the company’s stock.
Shares of CRSP opened at $36.37 on Friday. Crispr Therapeutics has a fifty-two week low of $16.70 and a fifty-two week high of $73.90.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Further Reading: Compound Interest and Why It Matters When Investing
Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.